Loading
Latest filing published 22 Oct 2018 for Avivagen Inc., €881.
Christopher John Boland appears in our data through filings on Avivagen Inc. shares, published by SEDI. Between 12 July 2012 and 18 October 2018, the trades on record add up to 11 filings.
Market trades split into 3 purchases (€3,670) and 1 sale (€9,881). Netting one side against the other leaves €6,211 of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 option exercises. 2018 to date brings 3 purchases and no sales.
The median purchase comes to €941. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.
Most recently, on 22 October 2018, the filings show an open-market purchase worth €941 in Avivagen Inc. Filings reach the SEDI feed a median of 4 days after the trade. This delay matters because a trade only becomes useful information once it is public. Source: insider filings from SEDI. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations